Table 1.

Antiretroviral therapy and drug resistance mutation over time in study subjects

Patient	Year	Antiretroviral therapy		mutations associated with resistance	Virus load Copies/ml
M	1993	AZT			n.d.
	1995	AZT, 3TC
	12/1997	d4T, 3TC
	1999				4700
	07/2004			RT: M41L, M184V, T215Y, (T39A, V60I, D121Y, I135T, I142V1, D177G, V179I, T200A, Q207E, L214f, L228H, Q334H)	26929
				PR: L63P, I13V, (V3I, K14R, S37N)
			CS p1/p6-gag: L449V, S451N
	08/2004	ATV/r, EFV
	01/2005				< 50
	04/2005	ATV/r, EFV, 3TC			< 50
W	08/2006			RT: M41L, T215D, (T39A, V60I, D121Y,135T,N137S,I142V, S162C, I202I/V, Q207E/K, l214F, l228H)	> 500.000
				PR: L63P, I13V, (E35D, S37N/S, S37N, V3I)
			CS p1/p6-gag: L449V, S451N
	09/2006	TVd, INV/r
	10/2008	TVd, ATV/r			< 40
	11/2008				1381
	12/2008				132
	02/2008				8515
	03/2009			RT: M41L, T215D, (T39A,V601I D121Y, K122E,135T,N137S,I142V S162C, I202IV, Q207E/K, L214F, L228H, V245M, A272P, T286A, E297K)
				PR: L63P, I13V, E35D
			CS p1/p6-gag: l449V, S451N
	04/2009	NVP, DRV/r
	06/2009				< 40
	11/2009				< 40

M = husband/suspected source of infection, W = case-patient